News

Mr LaPorte was recently retired as senior vice president of business development and general counsel from the company. Prior to Invacare, Mr LaPorte was a partner at Calfee,

In his new role, Dr Moerck will lead Valensa’s move into the next generation of high-performance plant-derived dietary supplements and functional food ingredients, which includes Valensa’s ‘direct to

Mr Weaver is primarily responsible for management of the financial operations of the company. Most recently, Mr Weaver served as CFO of Talyst, a pharmacy automation healthcare IT

The biologics pilot plant will allow UCB to further optimize the bio-manufacturing processes for its biological compounds under development, extending its knowledge and competencies in this field. This

Previously, Mr Williams was a founding member of the Partnership for Prevention, an organization of public and private sector representatives who focus on preventive healthcare policies. Mr Williams

Dr Henderson joins the Cytokinetics board of directors with over 30 years of experience in the life science industry. Since December 2000, Dr Henderson has served as a

The Phase I trial has been designed to compare pharmacokinetics in Parkinson’s patients of two formulations of DM-1992 and a generic version of Sinemet CR, a commercially available

Following the promising results generated in the frame of the initial collaboration established between Flamel and Merck Serono in 2007, Merck Serono has made the decision to exercise

These offices comprise more than 80% of Gentiva’s current pediatric care operations. Terms have not been disclosed. According to Gentiva, the transaction fits with its stated objective of